A single mutation in the 729 residue modulates human DNA topoisomerase IB DNA binding and drug resistance.
Human DNA topoisomerase I (hTop1p) catalyzes the relaxation of supercoiled DNA and constitutes the cellular target of the antitumor drug camptothecin (CPT). The X-ray crystal structure of the enzyme covalently joined to DNA and bound to the CPT analog Topotecan suggests that there are two classes of mutations that can produce a CPT-resistant enzyme. The first class includes changes in residues that directly interact with the drug, whereas a second class alters interactions with the DNA and thereby destabilizes the drug binding site. The Thr729Ala, that is part of a hydrophobic pocket in the enzyme C-terminal domain, belongs to a third group of mutations that confer CPT resistance, but do not interact directly with the drug or the DNA. To understand the contribution of this residue in drug resistance, we have studied the effect on hTop1p catalysis and CPT sensitivity of four different substitutions in the Thr729 position (Thr729Ala, Thr729Glu, Thr729Lys and Thr729Pro). Tht729Glu and Thr729Lys mutants show severe CPT resistance and furthermore, Thr729Glu shows a remarkable defect in DNA binding. We postulate that the maintenance of the hydrophobic pocket integrity, where Thr729 is positioned, is crucial for drug sensitivity and DNA binding.
Losasso
Carmen
C
Department of Biology, University of Padova, Via U. Bassi 58/B, Padua 35131, Italy.
Cretaio
Erica
E
Fiorani
Paola
P
D'Annessa
Ilda
I
Chillemi
Giovanni
G
Benedetti
Piero
P
D019943:Amino Acid Substitution; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D002166:Camptothecin / Q000494:pharmacology*; D002384:Catalysis; D004247:DNA / Q000378:metabolism; D004264:DNA Topoisomerases, Type I / Q000235:genetics / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D009154:Mutation; D011485:Protein Binding; D012441:Saccharomyces cerevisiae / Q000235:genetics; D013912:Threonine / Q000235:genetics; D059004:Topoisomerase I Inhibitors
D000972:Antineoplastic Agents, Phytogenic; D004791:Enzyme Inhibitors; D059004:Topoisomerase I Inhibitors; D013912:Threonine; D004247:DNA; D004264:DNA Topoisomerases, Type I; C528909:TOP1 protein, human; D002166:Camptothecin
Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6299-303
7603986
Cancer Res. 1993 Sep 15;53(18):4343-8
8395982
Drug Resist Updat. 1999 Oct;2(5):307-318
11504505
Science. 1998 Mar 6;279(5356):1534-41
9488652
Annu Rev Pharmacol Toxicol. 2001;41:53-77
11264450
J Biol Chem. 2007 Mar 30;282(13):9855-9864
17276985
J Biol Chem. 1997 May 9;272(19):12801-8
9139740
Cancer Res. 1995 Mar 15;55(6):1339-46
7882333
Cancer Res. 1989 Nov 15;49(22):6318-23
2553253
Mutat Res. 2003 Nov 27;532(1-2):173-203
14643436
J Biol Chem. 2000 May 19;275(20):15246-53
10809761
Nat Rev Cancer. 2006 Oct;6(10):789-802
16990856
J Mol Biol. 2004 Jun 11;339(4):773-84
15165849
J Biol Chem. 1995 Mar 17;270(11):6141-8
7890748
J Biol Chem. 2003 Oct 31;278(44):43268-75
12904303
J Biol Chem. 2002 Aug 23;277(34):30815-23
12077150
Mol Pharmacol. 1999 Dec;56(6):1105-15
10570037
Med Pediatr Oncol. 2000 Oct;35(4):385-402
11025469
J Biol Chem. 1998 Nov 20;273(47):31519-27
9813066
Science. 1998 Mar 6;279(5356):1504-13
9488644
Methods Mol Biol. 2001;95:291-301
11089241
Cell. 1985 Jun;41(2):541-51
2985282
J Biol Chem. 2000 Dec 29;275(52):41107-13
11016921
J Biol Chem. 2008 Feb 8;283(6):3305-3315
18056711
Cell. 1988 Dec 2;55(5):849-56
2847873
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15387-92
12426403
Nucleic Acids Res. 2006;34(18):5093-100
16990249
J Mol Biol. 2004 Feb 6;336(1):93-103
14741206
Biochem Biophys Res Commun. 1992 Oct 30;188(2):571-7
1332703